Karyopharm Therapeutics’ (KPTI) Outperform Rating Reaffirmed at Royal Bank of Canada

Royal Bank of Canada reaffirmed their outperform rating on shares of Karyopharm Therapeutics (NASDAQ:KPTI) in a research note issued to investors on Thursday,Benzinga reports. The brokerage currently has a $3.00 price target on the stock.

Several other brokerages also recently commented on KPTI. StockNews.com downgraded shares of Karyopharm Therapeutics from a “buy” rating to a “hold” rating in a report on Friday, November 22nd. HC Wainwright reaffirmed a “buy” rating and set a $7.00 price target on shares of Karyopharm Therapeutics in a research report on Thursday. Finally, Piper Sandler increased their price target on Karyopharm Therapeutics from $4.00 to $5.00 and gave the company an “overweight” rating in a research report on Wednesday, November 6th. One equities research analyst has rated the stock with a hold rating and four have assigned a buy rating to the company. Based on data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and an average price target of $5.00.

Karyopharm Therapeutics Stock Performance

KPTI opened at $0.61 on Thursday. The company’s fifty day moving average price is $0.66 and its two-hundred day moving average price is $0.76. Karyopharm Therapeutics has a 1-year low of $0.53 and a 1-year high of $1.70.

Karyopharm Therapeutics (NASDAQ:KPTI) last issued its quarterly earnings data on Wednesday, February 19th. The company reported ($0.24) EPS for the quarter, topping the consensus estimate of ($0.26) by $0.02. The company had revenue of $30.54 million during the quarter, compared to analysts’ expectations of $30.29 million. Equities analysts forecast that Karyopharm Therapeutics will post -0.71 earnings per share for the current year.

Institutional Trading of Karyopharm Therapeutics

A number of large investors have recently added to or reduced their stakes in the stock. Adage Capital Partners GP L.L.C. increased its stake in shares of Karyopharm Therapeutics by 46.3% during the 4th quarter. Adage Capital Partners GP L.L.C. now owns 6,319,842 shares of the company’s stock worth $4,274,000 after purchasing an additional 2,000,000 shares during the last quarter. Marshall Wace LLP increased its position in Karyopharm Therapeutics by 15.3% in the fourth quarter. Marshall Wace LLP now owns 2,401,413 shares of the company’s stock worth $1,633,000 after buying an additional 319,187 shares during the last quarter. GSA Capital Partners LLP increased its position in Karyopharm Therapeutics by 80.6% in the third quarter. GSA Capital Partners LLP now owns 1,775,700 shares of the company’s stock worth $1,474,000 after buying an additional 792,283 shares during the last quarter. Geode Capital Management LLC increased its position in Karyopharm Therapeutics by 2.7% in the fourth quarter. Geode Capital Management LLC now owns 1,392,314 shares of the company’s stock worth $942,000 after buying an additional 36,922 shares during the last quarter. Finally, Jane Street Group LLC increased its position in Karyopharm Therapeutics by 265.5% in the fourth quarter. Jane Street Group LLC now owns 748,306 shares of the company’s stock worth $506,000 after buying an additional 543,556 shares during the last quarter. Hedge funds and other institutional investors own 66.44% of the company’s stock.

Karyopharm Therapeutics Company Profile

Karyopharm Therapeutics Inc, a commercial-stage pharmaceutical company, discovers, develops, and commercializes drugs directed against nuclear export for the treatment of cancer and other diseases in the United States. The company discovers, develops, and commercializes novel and small molecule Selective Inhibitor of Nuclear Export (SINE) compounds that inhibit the nuclear export protein exportin 1 (XPO1).